Walleye Capital’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Walleye Capital’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-576,137	Closed	-$2.42M	–	5190
2023 Q1	$2.42M	Buy	576,137 +382,967	+198%	+$1.99M	0.04%	619
2022 Q4	$1.16M	Sell	193,170 -203,802	-51%	-$1.11M	0.02%	902
2022 Q3	$2.31M	Buy	+396,972	New	+$2.47M	0.04%	480
2022 Q2	–	Sell	-30,499	Closed	-$142K	–	2908
2022 Q1	$142K	Buy	+30,499	New	+$91K	﹤0.01%	1646

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Walleye Capital's CTIC Position: Q2 2023 in Review

Walleye Capital sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 576,137 shares — an estimated $2.42M sold.

Walleye Capital first reported a position in CTIC in Q1 2022 and held it in 4 quarters. The position peaked at $2.42M in Q1 2023. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Walleye Capital reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Walleye Capital sold 576,137 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $2.42M.
Walleye Capital first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q1 2022 and held it in 4 quarters.
Walleye Capital's CTI BioPharma Corp. (DE) Common Stock position peaked at $2.42M in Q1 2023.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Walleye Capital's 13F filing for Q2 2023, filed 14 Aug 2023.